Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective

Diabetes Research and Clinical Practice

Volumn 95, Issue 2, 2012, Pages 194-200

  Drabik, A ^a   Buscher G ^a   Sawicki, P T ^a   Thomas, K ^a   Graf, C ^b   Muller D ^a   Stock, S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b BARMER GEK Sickness Fund   (Germany)

Author keywords

Cost effectiveness; Diabetes mellitus type 2; Disease management; Life prolonging

Indexed keywords

AGED; AGING; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MANAGEMENT PROGRAM; DRUG COST; FEMALE; GERMANY; HEALTH CARE COST; HEALTH PROGRAM; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LIFE EXTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ROUTINE CARE; SURVIVOR;

AGED; AGING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; MALE; PROGRAM EVALUATION;

EID: 84856335072     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.09.015     Document Type: Article

References (33)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
2. International Diabetes Federation IDF diabetes atlas 2009, International Diabetes Federation, Brussels, Belgium. 4th ed.
3. Köster I., Huppertz E., Hauner H., Schubert I. Direct costs of diabetes mellitus in Germany - CoDiM 2000-2007. Exp Clin Endocrinol Diabetes 2011, 119(6):377-385.
4. Stock S.A., Redaelli M., Wendland G., Civello D., Lauterbach K.W. Diabetes - prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 2006, 23(3):299-305.
5. Franco O.H., Steyerberg E.W., Hu F.B., Mackenbach J., Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007, 167(11):1145-1151.
6. Hauner H. The costs of diabetes mellitus and its complications in Germany. Dtsch Med Wochenschr 2006, 131(Suppl. 8):S240-S242.
7. Schaufler T.M., Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010, 8(3):191-202.
8. §137f SGB V. At: [accessed 15.09.11]. http://www.gesetze-im-internet.de/sgb_5/_137f.html.
9. Busse R. Disease management programs in Germany's statutory health insurance system. Health Aff (Millwood) 2004, 23(3):56-67.
10. Stock S.A., Redaelli M., Lauterbach K.W. Disease management and health care reforms in Germany - does more competition lead to less solidarity?. Health Policy 2007, 80(1):86-96.
11. Linden A., Adams J.L., Roberts N. An assessment of the total population approach for evaluating disease management program effectiveness. Dis Manag 2003, 6(2):93-102.
12. Stock S., Drabik A., Büscher G., Graf C., Ullrich W., Gerber A., et al. German diabetes management programs improve quality of care and curb costs. Health Aff (Millwood) 2010, 29(12):2197-2205.
13. Drabik A, Büscher G, Thomas K, Graf C, Müller D, Stock S. Patients with type 2 diabetes benefit from primary care based disease management - a propensity score matched survival time analysis. Popul Health Manag; in press.
14. Miksch A., Laux G., Ose D., Joos S., Campbell S., Riens B., et al. Is there a survival benefit within a German primary care-based disease management program?. Am J Manag Care 2010, 16(1):49-54.
15. Polder J.J., Barendregt J.J., van Oers H. Health care costs in the last year of life - the Dutch experience. Soc Sci Med 2006, 63(7):1720-1731.
16. GKV Spitzenverband. DMP-Programmkostenpauschale. At: [accessed 15.09.11]. http://www.gkv-spitzenverband.de/DMP_Programmkosten.gkvnet.
17. Intitute for Quality and Efficiency in Health Care (IQWiG). Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten; 2009. At: [accessed 15.09.11]. https://www.iqwig.de/download/Methodik_fuer_die_Bewertung_von_Verhaeltnissen_zwischen_Kosten_und_Nutzen.pdf.
18. Sekhon J.S. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011, 42(7):1-52.
19. de Bruin S.R., Heijink R., Lemmens L.C., Struijs J.N., Baan C.A. Impact of disease management programs on healthcare expenditures for patients with diabetes, depression, heart failure or chronic obstructive pulmonary disease: a systematic review of the literature. Health Policy 2011, 101(2):105-121.
20. Van den Block L., Deschepper R., Drieskens K., Bauwens S., Bilsen J., Bossuyt N., et al. Hospitalisations at the end of life: using a sentinel surveillance network to study hospital use and associated patient, disease and healthcare factors. BMC Health Serv Res 2007, 7:69.
21. Levinsky N.G., Yu W., Ash A., Moskowitz M., Gazelle G., Saynina O., et al. Influence of age on medicare expenditures and medical care in the last year of life. JAMA 2001, 286(11):1349-1355.
22. Wilson D.M., Hewitt J.A., Thomas R., Mohankumar D., Kovacs Burns K. Age-based differences in care setting transitions over the last year of life. Curr Gerontol Geriatr Res 2011, Epub ahead of print. 10.1155/2011/101276.
23. Rosenzweig J.L., Taitel M.S., Norman G.K., Moore T.J., Turenne W., Tang P. Diabetes disease management in medicare advantage reduces hospitalizations and costs. Am J Manag Care 2010, 16(7):e157-e166.
24. Thiebaud P., Demand M., Wolf S.A., Alipuria L.L., Ye Q., Gutierrez P.R. Impact of disease management on utilization and adherence with drugs and tests: the case of diabetes treatment in the Florida: a Healthy State (FAHS) program. Diabetes Care 2008, 31(9):1717-1722.
25. Encinosa W.E., Bernard D., Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res 2010, 22:151-173.
26. Bundesversicherungsamt Bericht des Bundesversicherungsamtes zur vergleichenden Evaluation von strukturierten Behandlungsprogrammen bei Diabetes mellitus Typ 2. BVA; 2009.
27. Piehlmeier W., Renner R., Fahn J., Landgraf R. Ten years experience with the disease management programme PROSIT for diabetes. Diab Res Clin Pract 2006, 74(Suppl. 2):S205-S209.
28. Sönnichsen A.C., Winkler H., Flamm M., Panisch S., Kowatsch P., Klima G., et al. The effectiveness of the Austrian disease management programme for type 2 diabetes: a cluster-randomised controlled trial. BMC Fam Pract 2010, 11:86.
29. Pimouguet C., Le Goff M., Thiébaut R., Dartigues J.F., Helmer C. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ 2001, 183(2):E115-E127.
30. Graf C., Elkeles T., Kirschner W. Gibt es einen Selektionsbias im DMP Diabetes? Ergebnisse einer Versichertenbefragung von DMP-Teilnehmern und nichtteilnehmenden Diabetikern. Z Allg Med 2009, 85(2):74-81.
31. Schäfer I., Küver C., Gedrose B., von Leitner E.C., Treszl A., Wegscheider K., et al. Selection effects may account for better outcomes of the German disease management program for type 2 diabetes. BMC Health Serv Res 2010, 10:351.
32. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme GbR Qualitätssicherungsbericht 2009 - disease-management-programme in Nordrhein 2010, Echo Verlagsgruppe GmbH, Köln.
33. GKV Spitzenverband Kennzahlen der gesetzlichen Krankenversicherung; 2011. At: [accessed 15.09.11]. http://www.gkv-spitzenverband.de/upload/GKV_Kennzahlen_Booklet_Q4_2011-03_02_15951.pdf.